These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 2842480)

  • 1. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
    Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
    J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
    Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
    Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma].
    Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J
    Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EBV antibody titers in Italian patients with nasopharyngeal carcinoma.
    Pirodda E; Caliceti U; Testoni S
    J Exp Pathol; 1987; 3(4):479-83. PubMed ID: 2842481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits.
    Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT
    Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy.
    Shimakage M; Ikegami N; Chatani M; Yoshino K; Sato T
    Biken J; 1987 Jun; 30(2):45-51. PubMed ID: 2830879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand.
    Puthavathana P; Sutthent R; Vitavasiri A; Wasi C; Chantarakul N; Thongcharoen P
    Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.